Clinical efficacy and safety of sacubactril valsartan combined with trimetazidine in the treatment of chronic congestive heart failure
Objective To explore the efficacy and safety of sacubactril valsartan combined with trimetazidine in the treatment of chronic congestive heart failure.Methods 76 patients with chronic congestive heart failure were selected as study subjects,and were divided into group A and group B according to the lottery method,with 38 cases in each group.Group A was treated with enalapril + trimetazidine,and group B was treated with sacubactril valsartan + trimetazidine.Comparison was made on treatment effect,cardiac function indicators[left ventricular ejection fraction(LVEF),N-terminal-pro brain natriuretic peptide(NT-proBNP)levels,6-min walking distance(6MWD),and left ventricular end diastolic diameter(LVEDD)],incidence of adverse reactions,and hospitalization time between the two groups.Results The total effective rate of group B was 97.37%,which was higher than 81.58%of group A,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in LVEF,NT-proBNP,6MWD and LVEDD between the two groups(P>0.05).After treatment,group B had higher LVEF of(51.27±5.65)%than(47.84±5.25)%in group A,lower NT-proBNP of(867.87±66.56)pg/ml than(911.26±76.98)pg/ml in group A,longer 6MWD of(366.73±55.68)m than(314.54±65.65)m in group A,and smaller LVEDD of(53.12±5.23)mm than(56.76±5.78)mm in group A.The difference was statistically significant(P<0.05).The incidence of adverse reactions in group B was lower than that in group A,but difference was not statistically significant(P>0.05).The hospitalization time of(8.34±2.17)d in group B was shorter than(12.90±2.89)d in group A,and the difference was statistically significant(P<0.05).Conclusion The combination of sacubactril valsartan and trimetazidine in the treatment of chronic congestive heart failure is effective and has obvious improvement in cardiac function,which is a treatment plan with good clinical application value.
Chronic congestive heart failureSacubactril valsartanTrimetazidineCardiac function
NETL
NSTL
万方数据
维普
